Paradis M, Laperrière E, Larivière N
Département de médecine, Faculté de médecine vétérinaire, Université de Montréal, St. Hyacinthe, Québec.
Can Vet J. 1994 Jun;35(6):367-70.
Thyroid function was evaluated in 18 healthy dogs by thyrotropin (TSH) stimulation. Two dose regimens were used in each dog: 0.1 IU/kg body weight of freshly reconstituted lyophilized TSH and 1 IU/dog of previously frozen and stored TSH (up to 200 days), both given intravenously. Blood samples were collected prior to and at four and six hours after TSH administration. Serum was evaluated for total thyroxine concentrations by radioimmunoassay. All dogs were classified as euthyroid on the basis of response to 0.1 IU/kg body weight of freshly reconstituted TSH at four and six hours. The 1 IU dose of TSH, previously frozen for up to 200 days, induced increases in serum total thyroxine concentration over baseline at four and six hours that were not significantly different from those resulting from the use of the higher dose of fresh TSH. In all test groups, there were no statistically significant differences between total thyroxine concentrations at four and six hours post-TSH administration. It was concluded that an adequate TSH response can be achieved with the use of 1 IU of TSH/dog for clinically normal dogs between 29.0 kg and 41.6 kg body weight, even if this TSH has been frozen at -20 degrees C for up to 200 days. Further, blood collection can be performed at any time between four and six hours. Similar studies are needed to evaluate this new protocol in hypothyroid dogs and euthyroid dogs suffering nonthyroidal systemic diseases.
通过促甲状腺激素(TSH)刺激对18只健康犬的甲状腺功能进行了评估。每只犬使用两种剂量方案:体重0.1 IU/kg的新鲜复溶冻干TSH和每只犬1 IU的先前冷冻保存的TSH(最长200天),均静脉注射。在TSH给药前、给药后4小时和6小时采集血样。通过放射免疫测定法评估血清总甲状腺素浓度。根据对体重0.1 IU/kg新鲜复溶TSH在4小时和6小时的反应,所有犬均被分类为甲状腺功能正常。1 IU剂量的TSH(先前冷冻长达200天)在4小时和6小时时诱导血清总甲状腺素浓度相对于基线增加,与使用较高剂量新鲜TSH所产生的增加无显著差异。在所有测试组中,TSH给药后4小时和6小时的总甲状腺素浓度之间无统计学显著差异。得出的结论是,对于体重在29.0 kg至41.6 kg之间的临床正常犬,使用每只犬1 IU的TSH可实现足够的TSH反应,即使该TSH已在-20℃下冷冻长达200天。此外,可在4至6小时之间的任何时间进行采血。需要进行类似研究以评估该新方案在甲状腺功能减退犬和患有非甲状腺全身性疾病的甲状腺功能正常犬中的效果。